Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Chen
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L J
LJ
Medeiros
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H M
HM
Kantajian
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L
L
Zheng
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Gong
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K P
KP
Patel
Department of Hematology, Shanghai Xuhui Central Hospital, Shanghai, China.
H
H
Xiong
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W
W
Wang
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E
JE
Cortes
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Hu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001752:Blast Crisis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D059467:Transcriptome / Q000187:drug effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors